Total
turnover in the quarter was £7,147 million, up 40% AER, 40%
CER, reflecting strong performance in all three product groups.
Specialty Medicines included the positive impact of international
tender phasing, sales of Xevudy were £1,307 million and
contributed 25 percentage points of growth in the quarter. Vaccines
benefited from Shingrix
post pandemic recovery and retail buy-in in the US. General
Medicines reflects recovery of the antibiotics market as well as
the benefit of a favourable prior period RAR
adjustment.
Specialty Medicines
Specialty
Medicines sales in the quarter were £3,135 million, up 98%
AER, 97% CER, driven by consistent growth in all therapy areas
including sales of Xevudy.
Sales growth was up 16% AER, 15% CER excluding Xevudy.
HIV
HIV
sales were £1,181 million with growth of 15% AER, 14% CER in
the quarter. Growth was driven by new HIV products Dovato, Cabenuva, Rukobia, Juluca and Apretude and phasing. Phasing
contributed approximately two thirds of the growth, driven by
Tivicay International
tenders, US customer ordering patterns and US channel inventory
movement.
New HIV
products delivered sales of £446 million up 70% AER, 69% CER,
representing 38% of the total HIV portfolio. Sales of the oral two
drug regimens Dovato and
Juluca were £257
million and £133 million respectively with combined growth of
54% AER, 53% CER. Cabenuva,
the first long acting injectable, recorded quarterly sales of
£38 million. Apretude
delivered sales of £2 million.
Oncology
Oncology
sales in the quarter were £127 million, up 15% AER, 15% CER.
Zejula sales of £98
million, up 11% AER, 11% CER, continue to be adversely impacted by
diagnosis rates, particularly in the US. Sales of Blenrep, grew 19% AER, 19% CER to
£25 million in the quarter.
Immuno-inflammation,
Respiratory and Other
Immuno-inflammation,
Respiratory and Other sales were £520 million up 18% AER, 18%
CER. Benlysta sales were
£215 million, up 21% AER, 18% CER with growth in all regions,
including International sales of £26 million up 53% AER, 53%
CER. Nucala sales were
£295 million, up 16% AER, 16% CER including US sales of
£177 million up 18% AER, 15% CER on continued strong demand
and additional indications approval and launch. International
Nucala sales were £53
million up 26% AER, 31% CER.
Pandemic
Sales
of Xevudy were £1,307
million, with no sales in Q1 last year given launch in Q2 2021.
Sales were delivered in all regions, comprising US £770
million, Europe £311 million and International £226
million.
Vaccines
Vaccines
turnover grew 36% AER, 36% CER to £1,669 million, driven
primarily by Shingrix in
the US and Europe reflecting strong performance and the benefit of
a favourable comparator to Q1 2021 when sales were impacted by
COVID-19 related disruptions in several markets and lower CDC
purchases.
Meningitis
Meningitis
vaccines sales grew 12% AER, 12% CER% to £212 million mainly
driven by Bexsero (22% AER,
23% CER to £163 million) reflecting higher CDC purchasing in
the US.
Shingles
Shingrix grew >100% AER, >100 CER% to £698
million, primarily due to channel inventory build-up and demand
recovery in the US and higher demand in Germany. Launch markets
also contributed to increased sales reflecting continued geographic
expansion.
Established
Vaccines
Established
Vaccines grew 8% AER, 8% CER to £741 million mainly as a
result of higher CDC purchases of Infanrix/Pediarix and Hepatitis vaccines, US
demand and share growth for Boostrix, partially offset by lower
Synflorix, Cervarix and MMRV sales in
International.
General Medicines
General
Medicines sales in the quarter were £2,343 million, up 2% AER,
3% CER, with growth from Trelegy in all regions and the benefit
of a favourable prior period RAR adjustment, offsetting the impact
of generic competition in US, Europe and Japan.
Respiratory
Respiratory
sales were £1,535 million, up 3% AER, 3% CER. Trelegy sales were £340 million,
up 37% AER, 35% CER with strong growth in all regions. Advair/Seretide sales of £302 million
were down 14% AER, 14% CER on US and Europe generic competition,
partially offset by growth in International on targeted
promotion.
Other General
Medicines
Other
General Medicines sales were £808 million, flat at AER, up 3%
CER. Augmentin sales were
£129 million, up 42% AER, 51% CER reflecting rebound of the
antibiotic market post pandemic in the International and Europe
regions and in the US, a favourable prior period RAR adjustment was
reflected. This offsets ongoing impact of generic competition and
approximately two percentage points impact from the divestment of
GSK’s cephalosporin products in Q4 2021.
By
Region
US
In the
US, sales were £3,586 million, up 62% AER, 57% CER, including
Xevudy sales of £770
million contributing 34 percentage points of growth. HIV sales of
£697 million up 17% AER, 13% CER were driven by growth of new
HIV products, customer ordering patterns and lower channel
inventory burn. New HIV products delivered sales of £285
million up 72% AER, 66% CER, driven by Dovato and Cabenuva. Nucala and Benlysta both continued to grow
double-digits despite some year-end wholesaler destocking, while
Oncology growth continued to be impacted by diagnosis
rates.
Vaccine
sales were £892 million, up 77% AER, 71% CER. Growth was
driven by Shingrix
reflecting demand recovery and retail buy-in ahead of a price
increase. Meningitis, Hepatitis, Infanrix/Pediarix and Boostrix sales all grew in the quarter
reflecting CDC purchasing patterns and demand recovery. General
Medicines sales were £811 million up 7% AER, 4% CER,
benefiting from a favourable prior period RAR adjustment.
Trelegy sales continued
strong performance on growth of the single inhaler triple therapy
market and demand.
Europe
In
Europe, sales were £1,660 million, up 32% AER, 36% CER,
including Xevudy sales of
£311 million contributing 25 percentage points of growth. HIV
sales were £299 million up 4% AER, 8% CER driven by
Dovato. Strong double-digit
growth continued in the quarter on Benlysta, Nucala and Oncology
assets.
Vaccine
sales were £409 million, up 33% AER, 38% CER. Growth was
driven by Shingrix sales of
£160 million, up >100% AER, >100% CER on strong demand
in Germany post pandemic and channel re-stocking. General Medicines
sales were £503 million down 7% AER, 4% CER, with ongoing
generic competitive pressures on Seretide, partly offset by strong
demand for Trelegy and
growth of Augmentin on
rebound of the antibiotic market post the pandemic.
International
International
sales were £1,901 million, up 17% AER, 20% CER, including
Xevudy sales of £226
million contributing 14 percentage points of growth. HIV sales were
£185 million up 26% AER, 30% CER primarily driven by tender
phasing. Combined Tivicay
and Triumeq sales were
£148 million with growth of 21% AER and 25% CER. Nucala and Benlysta both continued to grow
strongly, due to Japan’s biologicals market growth and
China’s National Reimbursement Drug List approval,
respectively.
Vaccine
sales were £368 million, down 11% AER, 9% CER primarily
reflecting phasing of public tenders. General Medicines sales were
£1,029 million up 2% AER, 6% CER. Respiratory sales of
£480 million were up 1% AER, 4% CER. Strong growth of
Trelegy in Japan, China and
Canada, and growth of Seretide on targeted promotion, offset
impact of generic competition and lower allergy season in Japan.
Other General Medicines sales of £549 million, up 4% AER, 8%
CER reflect growth of Augmentin on rebound of the antibiotic
market post the pandemic.
|